Fusion Antibodies plc provided revenue guidance for the full year ending 31 March 2019. As trading in the second half of the financial year to date has significantly improved from first half, due to the uncertain timing of closure of a number of potential substantial orders revenues for the full year are now expected to be materially below current market expectations but not less than £2.1 million. After first half 2019, order levels picked up significantly from October 2018 onwards such that revenues in second half 2019 are expected to exceed all previous six-month periods. Total orders received in second half 2019 to date have exceeded £1.9 million (first half 2019: £1.2 million, second half 2018: £0.8 million) with more in the pipeline. In excess of £1.1 million of these orders will not be fulfilled and therefore recognized until the next financial year.